Found: 16
Select item for more details and to access through your institution.
Vive la différence.
- Published in:
- Organists' Review, 2013, v. 99, n. 3, p. 77
- By:
- Publication type:
- Article
Memories are made of this.
- Published in:
- Organists' Review, 2011, v. 97, n. 2, p. 92
- By:
- Publication type:
- Article
Congress Administrator.
- Published in:
- Organists' Review, 2011, v. 97, n. 1, p. 98
- By:
- Publication type:
- Article
Masters of our own destiny?
- Published in:
- Organists' Review, 2011, v. 97, n. 1, p. 86
- By:
- Publication type:
- Article
Important announcement.
- Published in:
- Organists' Review, 2010, v. 96, n. 3, p. 89
- By:
- Publication type:
- Article
Back to the Future!
- Published in:
- Organists' Review, 2010, v. 96, n. 3, p. 86
- By:
- Publication type:
- Article
It's good to talk.
- Published in:
- Organists' Review, 2010, v. 96, n. 2, p. 92
- By:
- Publication type:
- Article
Do you want to know a secret?
- Published in:
- Organists' Review, 2010, v. 96, n. 1, p. 97
- By:
- Publication type:
- Article
Statutory report of meetings.
- Published in:
- 2009
- By:
- Publication type:
- Proceeding
What's in it for me?
- Published in:
- Organists' Review, 2009, v. 95, n. 4, p. 95
- By:
- Publication type:
- Article
The honeymoon's over -- now for the wedding.
- Published in:
- Organists' Review, 2009, v. 95, n. 3, p. 95
- By:
- Publication type:
- Article
Correction.
- Published in:
- 2008
- By:
- Publication type:
- Correction notice
A message from your new Honorary General Secretary.
- Published in:
- Organists' Review, 2008, v. 94, n. 3, p. 92
- By:
- Publication type:
- Article
Your Letters.
- Published in:
- 2006
- By:
- Publication type:
- Letter
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037).
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, p. 1, doi. 10.1177/1758835920975352
- By:
- Publication type:
- Article
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response.
- Published in:
- JNCI Cancer Spectrum, 2023, v. 7, n. 6, p. 1, doi. 10.1093/jncics/pkad077
- By:
- Publication type:
- Article